

**REMARKS**

**Status of the Claims:**

Claims 1 – 75 are currently pending.

Claims 1 – 20 and 54 – 75 are currently cancelled.

**Response to Restriction Requirement**

The Examiner has required restriction of the Application under 35 U.S.C. § 121 and 372 to one of ten groups of claimed inventions. Office Action page 2. These groups are the following:

**Group I** (claims 1 – 19) drawn to a distinct peptide comprising a distinct amino acid sequence of the formula G-K-A-X<sub>1</sub>-X<sub>2</sub>-X<sub>3</sub>, wherein at least one of X<sub>1</sub> – X<sub>3</sub> is arginine

**Group II** (claims 20) drawn to a polynucleotide encoding a distinct peptide comprising a distinct amino acid sequence of the formula G-K-A-X<sub>1</sub>-X<sub>2</sub>-X<sub>3</sub>, wherein at least one of X<sub>1</sub> – X<sub>3</sub> is arginine

**Group III** (claims 21 – 53) drawn to a composition comprising a peptide comprising a distinct amino acid sequence of the formula G-K-A-X<sub>1</sub>-X<sub>2</sub>-X<sub>3</sub>, wherein at least one of X<sub>1</sub> – X<sub>3</sub> is arginine

**Group IV** (claims 54 – 57) drawn to a method of producing a prodrug comprising a distinct peptide comprising a distinct amino acid sequence of the formula G-K-A-X<sub>1</sub>-X<sub>2</sub>-X<sub>3</sub>, wherein at least one of X<sub>1</sub> – X<sub>3</sub> is arginine

**Group V** (claims 58 – 64 ) drawn to a method of treating an hK2-producing cell disorder

**Group VI** (claims 65 – 71) drawn to a method of detecting hK2-producing tissue

**Group VII** (claim 72) drawn to a method of selecting a hK2-activatable prodrug

**Group VIII** (claim 73) drawn to a method of determining the activity of hK2 in a sample containing hK2

**Group IX** (claim 74) drawn to a method of imaging hK2-producing tissue

**Group X** (claim 75) drawn to a method of identifying a peptide sequence which can be a substrate for hK2

**Applicants elect Group III (claims 21 – 53) without traverse.** Applicants hereby cancel claims 1 – 19 and 54 – 75, drawn to the non-elected groups, without prejudice or disclaimer. Applicants reserve rights to file one or more divisional applications on the non-elected groups at a later date.

The Examiner has also required an election of a distinct peptide sequence upon which the elected group is to be searched. Office Action page 4. **Applicants elect G-K-A-F-R-R as the peptide sequence of Group III ( $X_1 = F$ ,  $X_2 = R$ ,  $X_3 = R$ ).** This election is also made without traverse.

### CONCLUSION

Claims 21 – 53 remain pending in the application. Applicants respectfully request that the Examiner now allow examination of these remaining claims to proceed on their merits.

Although Applicants do not believe any additional fees other than the extension of time are due, the Director is hereby authorized to charge any fees or credit any overpayment due to Deposit Account Number 23-2426 of Winstead PC (referencing matter number 50562-P001US).

If the Examiner has any questions or comments concerning this paper or the present application in general, the Examiner is invited to call the undersigned at 713-650-2782.

Respectfully submitted,

WINSTEAD PC

Attorneys/Agents for Applicant

Date: May 7, 2009

By: /William P. Ramey, III/  
William P. Ramey, III, Reg. No. 44,295

ATTORNEY DOCKET NO  
50562-P001US

PATENT  
U.S. Ser. No. 10/535,351

Mail correspondence to :

WINSTEAD P.C.  
P. O. Box 50784  
Dallas, Texas 75201  
Tel: 713.650.2764  
Fax: 214.745.5390